Shows
pharmaphorum PodcastBiotech’s biggest challenge isn’t scientific, but political – with James Roosevelt JrAmid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political.
In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy, and grandson of FDR, as well as Advisory Board Member for Pluri Inc, discusses regulatory bottlenecks and their stalling effect on cell-based therapies, as well as the real dynamics behind FDA reform, and why biotech CEOs must become more fluent in policymaking now.
You can listen to episode 215 of the pharmaphorum podcast in the player below, d...
2025-11-0411 min
pharmaphorum PodcastOn targeted radiotherapeutics, with Marc HedrickRadiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding tissue are few. And this is where targeted radiotherapeutics come in.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Marc Hedrick, president and CEO of Plus Therapeutics, a clinical stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today and for the future.
You can listen to episode 214 of the pharmaphorum podcast in the...
2025-10-3034 min
pharmaphorum PodcastTowards one, cohesive AI workflow: In conversation with Ilya BurkovIn a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company building one of the world’s leading AI infrastructure companies.
Burkov discusses the deployment of AI and cloud-native infrastructure for improving the speed and indeed quality of drug development, as well as why access to compute not enough and how GenAI is helping pharma teams integrate real-world evidence into the pipeline.
You can listen to episode 213 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it...
2025-10-2812 min
pharmaphorum PodcastCollaborating on a connected platform journey, with Alexander Alex and Florian SchnappaufBayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM, taking that relationship, and Bayer’s connected platform journey, to the next level.
In order to discuss this migration further, pharmaphorum spoke with Alexander Alex, head of Veeva Platform at Bayer, and Florian Schnappauf, vice president of enterprise commercial strategy at Veeva.
Alex and Schnappauf explain how Vault CRM is a step-change for companies like Bayer, and discuss the benefits of being able to reflect the whole customer journey on a sing...
2025-10-2129 min
pharmaphorum PodcastESMO25: Patient-centric oncological futures with Boehringer IngelheimAs pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-small cell lung cancer (NSCLC), tumour shrinkage observed by investigator review - Boehringer Ingelheim is racing to expand its label.
As the company reported new data at the Congress from the phase 1b Beamion LUNG-1 study, underpinning the approval of zongertinib (Hernexeos) as a second-line therapy, web editor Nicole Raleigh spoke with Lykke Hinsch Gylvin, chief medical officer of Boehringer Ingelheim, and Itziar Canamasas, Boehringer's head of oncology, offsite in Berlin.
Discussing...
2025-10-1914 min
pharmaphorum PodcastSmoothing a contract pathway through uncertainty: In conversation with Neal MasiaBack in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump administration this year.
Tune into today’s podcast for an exploration of the potential scenarios Masia mused might arise, as well as his insights on the 340B Program, PBMs, and risk-based contracts.
You can listen to episode 210 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple...
2025-10-1630 min
pharmaphorum PodcastAllosteric small molecule therapies in PD, with Gene MackAs Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space.
Mack discusses the company’s progress in this field, and explores where next in terms of the unmet needs of Parkinson’s disease and the potential of this specific area of R&D in the future.
You can listen to episode 209a of the pharmaphorum podcast in the player below, download the episode to your comput...
2025-10-0920 min
pharmaphorum PodcastImproving ROI on AI investments and data quality, with Dr Jay AndersHealthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements.
In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the only way organisations can solve all three of those problems is by first solving data quality issues.
Anders talks about this data quality crisis, and the financial and operational impacts of the current situation, and explains why providers must ensure clinical data is validated...
2025-10-0717 min
pharmaphorum PodcastThe importance of being disruption ready, with Brandon PenceThe cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed President and COO of Fujifilm Biosciences, a company previously known as Fujifilm Irvine Scientific, about the cell culture media field.
Pence also discusses end-to-end life sciences capabilities to create an accelerated path toward greater patient access for advanced care, as well as the shift of late to...
2025-10-0319 min
pharmaphorum PodcastAgentic AI, culture shifts, and commercialisation today: Anthony Cilento post-Axtria Ignite 2025In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally.
Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’s required by way of a culture shift more generally, as well as speaking to the changes necessary in the advanced therapies space when it comes to commercialisation.
You can listen to episode 206a of the pharmaphorum podcast in the pla...
2025-09-3011 min
pharmaphorum PodcastDoing good in people’s lives: Amy Burroughs discusses CMLChronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatments for CML, the potential of allosteric TKIs, and the wider oncological landscape today.
You can also listen to episode 205a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to...
2025-09-1110 min
pharmaphorum PodcastPharma and health advertising: Brian Coane on the necessity of humourWhen it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and health advertising.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Coane, health partner at creative agency Leith, who talks sensitivity, maximum impact, and overcoming the fear of getting it wrong.
After all, dull ads can lead to the dreaded ‘beige tax’.
You can also listen to episode 204a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and su...
2025-09-0917 min
pharmaphorum PodcastThe glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investmentBiotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversation focused on the current ‘perfect storm’ in biotech and why the skies might not be quite as grey and foreboding as at first feared.
Pashazadeh discusses how developers, CDMOs, CROs, and all...
2025-09-0526 min
pharmaphorum PodcastFH25: The intersection of tech, science & design with Unity StoakesThis year marks the 10th anniversary of Frontiers Health.
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Unity Stoakes, president and co-founder of Startup Health and Advisory Board Member at The NeuroTech Collider Lab, University of California, Berkeley.
Stoakes has spent 30+ years at the intersection of tech, science, and design, operating with the focal goal of transforming global health. And Frontiers Health provides a buzz, a magic, and a vibe to attain that.
For Stoakes, Frontiers Health is all about the people, and t...
2025-09-0310 min
pharmaphorum PodcastChanging the drug development treatment paradigm: Hilary Eaton on AI and LLMsIn a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine.
Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performance based on size and computing power – apply to biology.
You can also listen to episode 202a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Po...
2025-09-0223 min
pharmaphorum PodcastIncreasing trial efficiency: Adityo Prakash talks small datasets, real-world scenarios, and organoidsCharacterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient.
In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a clinical-stage pharmaceutical company based in Fremont, California that is developing several drug discovery programmes in cardiometabolic diseases and cancer using molecular physics and artificial intelligence.
Prakash discusses development of new AI technologies to handle the small, sparse datasets typical of real-world scenarios...
2025-08-2817 min
pharmaphorum PodcastFH25: Ten years at the forefront of health innovation, with Kristin MilburnThis November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary.
To mark the occasion, pharmaphorum is proud to launch a special limited-edition podcast series, bringing you conversations with the people who’ve helped define the conference over the years – and those driving the next wave of innovation.
We’re kicking things off with a very special guest: Kristin Milburn, SVP, marketing ecosystem & strategy at Frontiers Health. Having served across several roles – both on and off stage – she offers a rare perspective on what makes the conference so unique, and what attendees can expect from this special...
2025-08-2713 min
pharmaphorum PodcastThe TechBio way: Brendan Frey talks genomics, AI, and RNAOverall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation working on a genome biology foundation AI platform.
From Nobel Prizes connected to the company’s work in the field, to mining RNA bi...
2025-08-1426 min
pharmaphorum PodcastAdvancing the frontier of cancer diagnostics: Post-ASCO with Eric MatthewsCaris Life Sciences was founded in 2008 with a simple but powerful purpose – to realise the potential of precision medicine and help improve the lives of as many people as possible.
In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life Sciences, about advancing the frontier of cancer diagnostics and treatment with breakthroughs in AI-driven pathology, real-world clinico-genomic data, and more.
These other ASCO 2025 and post-ASCO conversations can be found here.
You can also listen to episode 198a of the pharmaphorum podcast in the player below...
2025-08-1208 min
pharmaphorum PodcastCompliance baked into the design core: On AI in life sciences with Florian SchnappaufWhen it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real necessity. And 2025 is becoming a turning point wherein practical, embedded AI begins to scale.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise commercial strategy Europe, at Veeva Systems.
The conversation covers commercial model evolution, precision engagement, the importance of quality data in a personalisation strategy, and – of course – compliance.
You can also listen to episode 197a of the pharmaphorum podca...
2025-08-0719 min
pharmaphorum PodcastEnhancing anti-tumour activity: A post-ASCO conversation with Dan SchmittMetastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases.
At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previously untreated patients with mPDAC.
In a post-ASCO pharmaphorum podcast, Dan Schmitt, CEO of Actuate, discussed the data, as well as the Congress as a whole, and his hopes for the future of oncology more generally.
You can also listen...
2025-07-3128 min
pharmaphorum PodcastRedefining the Future of Melanoma Treatment: Scancell's Bold Step ForwardMelanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L’Huillier, CEO of Scancell, about how the company develops novel immunotherapy products for the treatment of multiple cancers, as well as its recently announced partnership with the NHS Cancer Vaccine Launch Pad, and latest data release from the Phase 2 cl...
2025-07-2919 min
pharmaphorum PodcastPost-ASCO 25: Pamela Tenaerts on CGTs and digital-first long-term follow-upWhen it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments extremely limited, given the 15 years that patients must still engage with the trial after receiving the medication.
In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable, about the company’s new digital-first model to handle long-term follow-up care for cell and gene therapy cancer trials.
Tenaerts explains how the company’s approach prioritises patient comfort, simplifies trial execution, and enhances patient engagement, and is designed spec...
2025-07-2221 min
pharmaphorum PodcastImmune mediation, B-cell depletion, and female leadership – with Aoife BrennanIn a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, and Brennan talks about the potential of B-cell depletion therapies, as well as the challenges and opportunities in developing novel biotechnology.
Brennan also speaks to being a female leader in this field.
You can also listen to episode 191a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the ser...
2025-07-1725 min
pharmaphorum PodcastBen Sidders on integrating causality in AI for R&D successFor AI to truly revolutionise drug discovery, it must move beyond pattern recognition and predictive analytics to include causality, which is essential for technical and regulatory success in drug discovery.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ben Sidders, chief scientific officer at Biorelate, a company leveraging advanced data science methods to transform the focus and impact of drug discovery and development.
Sidders discusses how integrating causality in AI for biotechnology can drive greater R&D success, and more generally about how AI can contribute meaningfully and transparently to the advancement...
2025-07-1515 min
pharmaphorum PodcastOn nuclear medicine and oncology, SHINE technologiesRadiopharmaceutical therapy has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies, such as in oncology.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Greg Piefer, founder and CEO of SHINE Technologies, a nuclear fusion company mastering more immediate applications of fusion – such as in producing cancer-fighting medicine.
Piefer provides an overview of the nuclear medicine field and discusses clinical research that demonstrates that radiopharmaceuticals substantially improve the overall survival of patients with certain types of cancer. Additionally, the conversation touches upon why the US is...
2025-07-1025 min
pharmaphorum PodcastUnicorns, AI, and the future of health: Highlights from HLTH Europe 2025The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands today – and where it’s headed next.
Amid economic uncertainty and shifting regulatory priorities, pharma, health tech, and care delivery are all racing to prove value and scale innovation. In this special extended episode of the pharmaphorum podcast, Deep Dive editor Eloise McLennan sat down with editor-in-chief Jonah Comstock for a candid debrief on the key themes, hot topics, and hallway conversations that shaped the event in Amsterdam.
Fr...
2025-07-081h 04
pharmaphorum PodcastOn patient-centric treatment decisions and the value of quantitative methodologies, in conversation with Marc BuyseIn today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' perspective in any treatment decision.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, about his recent work as one of the editors of – and a chapter contributor to – the first edition of "𝘏𝘢𝘯𝘥𝘣𝘰𝘰𝘬 𝘰𝘧 𝘎𝘦𝘯𝘦𝘳𝘢𝘭𝘪𝘻𝘦𝘥 𝘗𝘢𝘪𝘳𝘸𝘪𝘴𝘦 𝘊𝘰𝘮𝘱𝘢𝘳𝘪𝘴𝘰𝘯𝘴: 𝘔𝘦𝘵𝘩𝘰𝘥𝘴 𝘧𝘰𝘳 𝘗𝘢𝘵𝘪𝘦𝘯𝘵-𝘊𝘦𝘯𝘵𝘳𝘪𝘤 𝘈𝘯𝘢𝘭𝘺𝘴𝘪𝘴", recently published by the Routledge Taylor & Francis Group.
The conversation explores generalised pairwise comparisons (or GPCs), applications in various disease areas, implications for regulatory approvals and benefit-risk analyses, and considerations for patient-centricity in clinical research and treatment decisions.
You can also listen to episode 189a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and sub
2025-07-0316 min
pharmaphorum PodcastMaximising value by uniting the digital backbone: On a new Novo Nordisk and Veeva partnershipAt this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical development.
In this episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Stephanie Bova, chief digital officer at Novo Nordisk, and Rik van Mol, SVP R&D and Quality at Veeva, about the partnership, Novo aiming to accelerate clinical trials and launches by uniting business and IT on the Veeva Development Cloud to enhance collaboration, automation, and data consistency.
It’s a mutual collaboration for addressing challenges and...
2025-07-0113 min
pharmaphorum PodcastThe changing landscape of drug clinical assessment: Tommy Bramley on the JCAThe JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tommy Bramley, SVP of market access and healthcare consulting at Cencora, about the JCA, as yet unanswered questions (at the time of the conversation) and the key challenges facing manufacturers.
Bramley also discusses...
2025-06-2418 min
pharmaphorum PodcastPrecision, speed, impact: Evolving mass spectrometry for medical scienceOriginally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Melissa Sherman, CEO of MOBILion Systems, a company pioneering next-generation separation science, by innovating best-in-class instruments that deeply, accurately, and efficiently characterise complex molecules.
Sherman discusses the practical impact of this new technology for R&D, MOBILion's work with mass spectrometry technology at the moment, and the future horizon for this and NGS.
You can also listen to episode 186a of the pharmaphorum po...
2025-06-1919 min
pharmaphorum PodcastTreating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapyOsteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours.
Describing the current treatment landscape for primary and secondary bone cancer, Romness explains the potential of their own – OST-HER2, a bioengineered bacterial immunotherapy based on...
2025-06-1318 min
pharmaphorum PodcastThe need for a science-first mindset: The vaccine landscape todayAs has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and diseases like whooping cough and measles have seen a worrying resurgence due to anti-vaxxers. And not just in the US.
In a new pharmaphorum podcast, Rebecca Catterick, General Manager for Vaccines, UK & Ireland, at Sanofi, discusses this decline in vaccination rates, as well as what can be done to turn the situation around.
Catterick explores the role of the UK Labour Government’s Child Health Action Plan, aligning as it does with NHS vaccination strate...
2025-05-2319 min
pharmaphorum PodcastEAPs: Market access outside of the US and Western EuropeEarly access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean.
Market access strategies in many international markets do not function the same way as they do in the US or Western Europe and require a different approach. Zorlular explains how EAPs can drive revenue for pharmaceutical companies from international unlicensed markets, but that...
2025-05-1913 min
pharmaphorum PodcastThe value of a partner, globally and locallyWith the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead.
Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP & International Managing Director at Alloga Europe and ICS, which are part of Cencora – and the conversation dives into takeaways such as the increase in smaller biotech companies taking their product to market on their own, what is n...
2025-05-0922 min
pharmaphorum PodcastAI in drug development: The real hurdle is implementationIt can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI.
Stelzer discusses the need for greater coordination within the pharmaceutical industry, particularly between life sciences and software engineering and explains how bridging the cultural divide can significantly enhance the...
2025-05-0112 min
pharmaphorum PodcastPatients as active consumers of care: AI-driven personalisation in pharma marketingTherapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bill Grambley, CEO of AllazoHealth, for a conversation on leveraging AI for marketing, as well as medication initiation and adherence.
Grambley discusses how AI can be leveraged to create highly personalised patient engagement strategies, ta...
2025-04-2924 min
pharmaphorum PodcastDriving the drug discovery pipeline: The value of organ-on-a-chip MPSIn a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs).
Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated. What NAMs permit is a screening of new drugs, of whatever entity – chemical or biological – to better predict how they will behave when put into a patient, says Kostriezewski.
From metabolic to neurological diseases, as well...
2025-04-2218 min
pharmaphorum PodcastIntelligent regulatory compliance and improved patient outcomesAcross the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outcomes through intelligent regulatory compliance.
For both pharma and medical device companies, time and bandwidth are the number one challenge RA professionals face, closely followed by costs and budgetary pressures (the latter being a more pronounced...
2025-04-1615 min
pharmaphorum PodcastPrevention for a healthier, more productive societyIn a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare.
Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and exciting possibilities from the panel discussion.
Prevention is increasingly seen as contributing to a healthier and more productive society. But, as healthcare resources are stretched and medical science is accelerating, the question remains: how do we m...
2025-04-1515 min
pharmaphorum PodcastSafeguarding the pharmaceutical supply chainAs we hear of the volcanic and seismic activity taking place in Iceland this week, pharmaphorum turns back to a conversation with Dean Alms, CPO of Aravo, on how extreme weather highlights the need to make adequate supply chain preparations for the seasons in which the planet pulls out all the stops with the worst of its natural disasters.
Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency protocols and drug reserves to be in place in the worst-case scenarios, and permits plants to return to...
2025-04-0213 min
pharmaphorum PodcastGenAI and the revolution of drug developmentIt takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life sciences sector can speed up the process, wiping months or even years off that average.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development.
Though it might seem an obvious path, not all life sciences companies are jumping on the bandwagon to adopt GenAI. Instead, many...
2025-03-0511 min
pharmaphorum PodcastPatient-focused manufacturing models for personalised therapiesUnique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs into medicines developed rapidly and robustly to - ultimately - end cancer.
Taking learnings from the monoclonal antibody field to come up with a fit-for-purpose solution, Bock discusses his work in the joint venture between t...
2025-02-2822 min
pharmaphorum PodcastPaediatric rare diseases: Children are not small adultsAround 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients dying before the age of five, the need for different treatment methods for children is clear.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Children’s National Medical Center.
The conversation touches upon incentivisation for manufacturers to develop drugs to treat rare diseases, addressing age-appropriate formulations and recognising the metabolic differences between children and ad...
2025-02-2016 min
pharmaphorum PodcastDefining, building, and implementing in the next wave of biopharma R&DIn a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma breakthroughs.
PharmaLex’s Dr Christian Schneider, VP & Chief Medical Officer, Clinical Development Services, together with Dr Christelle Boileau, Director of Regulatory Development Strategy and IPD solution lead at PharmaLex, which is part of Cencora, explore the many challenges faced across the clinical trial landscape when it comes to new therapies, including ATMP development.
From preclinical to market access and regulatory considerations, Dr Boileau warns that development is not a...
2025-02-1325 min
pharmaphorum PodcastInsights from JP Morgan Healthcare 2025: Key trends shaping the pharma industryThe JP Morgan Healthcare Conference remains one of the most influential events for the life sciences sector, setting the stage for major deal-making, investment trends, and strategic shifts that will define the year ahead.
Keen to capture all the key trends and talking points from this year’s event, pharmaphorum editor-in-chief, Jonah Comstock, hit the ground running in Philadelphia, live blogging key sessions and interviewing experts to find out what industry insiders foresee for 2025.
In this special extended episode of the pharmaphorum podcast, Jonah sits down with Deep Dive editor, Eloise McLennan, to break down the key...
2025-02-061h 04
pharmaphorum Podcast‘Show me the molecule’ – On synthetic biology and cutting through AI hypeTherapeutic antibodies are a vital weapon in combating diseases such as cancer, but developing these treatments through conventional methods is slow and unreliable.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug discovery company pioneering the discovery of next-generation therapeutic antibodies in order to solve this predicament.
Dr Field speaks to how can industry cut through the hype that surrounds AI and optimally assess the technical underpinnings of an AI proposition in medicine. He describes how LabGenius overcomes the so-called “cognition barrier” by usin...
2025-02-0415 min
pharmaphorum PodcastSimulated clinical trial populations and AI scalabilityAI might still be in the modish buzzword stage, but discussions exploring the potential for its scaling within life sciences are critical.
In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores the potential for scaling advanced technologies in the biopharmaceutical industry.
From digital twins and insilico modelling and the potential to reduce experimentation in human populations with simulated populations and differently designed trials, to document authoring and automation for time-saving purposes – the conversation on leveraging AI turns also...
2025-01-3029 min
pharmaphorum PodcastRare disease and the women's health gapFor women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every one man, and the women’s health gap more generally.
Schranz explains the importance of developing a more individualised approach to management and treatment of PBC for each patient and discusses Ipsen’s PB...
2025-01-2315 min
pharmaphorum PodcastFrom science fiction to reality: AI in drug developmentWith about 92% of new drugs failing in human clinical trials, pharma companies face tremendous financial losses and, more importantly, development and delivery of potentially life-saving treatments are woefully delayed.
In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about how AI could revolutionise preclinical research and accelerate the development of potentially life-saving drugs, safely.
Exploring the notion of 3D organ modelling, combining AI and ‘advanced’ biology such as organ-on-chip, and delving into his research passion of the rare diseases space, including FragileX, Bentwich explains that t...
2025-01-1521 min
pharmaphorum PodcastPrecision medicine, NGS, and the quantum leap in biomarkersIn a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.
Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent company, and that collaboration’s investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company’s value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions.
That included...
2024-12-1823 min
pharmaphorum PodcastInvestment outlook: Key takeaways from LSX USAInvestment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and accelerating the development of life-changing therapies. And so, it was no surprise that the 2024 LSX USA Congress in Boston attracted life sciences innovators and decision-makers from around the world, eager to explore the latest trends shaping the industry.
Among those attendees was pharmaphorum’s editor-in-chief, Jonah Comstock, who took to the floor to uncover the trends and talking points set to influence investment decisions in the coming months.
In this special episode of the pharmaphorum podcast, Jonah sat down with De...
2024-10-0433 min
pharmaphorum PodcastOncology today: Eversana and pharmaphorum at ESMO 2024The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific development, ever seeking to address unmet patient needs.
So it was that pharmaphorum Web Editor Nicole Raleigh found a quiet spot onsite in Barcelona this year to catch with experts from EVERSANA and discuss their takeaways from the 2024 conference. Tune in to hear more from: Ann Marie Robertson, Chief Commercial Officer, EVP, EVERSANA COMPLETE Oncology, EVERSANA; Barry Vucsko, Senior Vice President, Client Services and Business Development Leader, EVERSANA INTOUCH...
2024-09-2518 min
pharmaphorum PodcastHeadlines and hot topics from ASCO and BIOThis week, pharmaphorum editor-in-chief Jonah Comstock headed to not one but two back-to-back events in the US. Starting with the American Society of Clinical Oncology’s (ASCO) annual conference in Chicago, before hitting the floor at the BIO International Convention in Boston, there was plenty of innovation, news, and expert knowledge on display.
Fresh from the floor of BIO International, Jonah sat down with pharmaphorum Deep Dive editor Eloise McLennan to reflect on the biggest topics and trends from each event – and the impact these developments may have on pharma over the coming months.
2023-06-0943 min
pharmaphorum PodcastKey themes from JP Morgan, with Paul Tunnahpharmaphorum Editor-in-Chief Jonah Comstock and pharmaphorum Founder Paul Tunnah headed to San Francisco this week for the JP Morgan conference, the annual elbow-rubbing opportunity for biotech bigwigs. This is the first time the show has been back in person since COVID, and, despite some less than ideal weather, attendees were excited to resume in person collaboration.
2023-01-1220 min
pharmaphorum PodcastWhat we heard and saw at HLTH22, with Matthew Holtpharmaphorum Editor-in-Chief Jonah Comstock traveled to Las Vegas last week with thousands of other healthcare stakeholders for the HLTH 2022 conference.
In this post-show edition of the pharmaphorum podcast, Jonah welcomes Matthew Holt, editor of The Healthcare Blog and former digital health event organiser, to discuss the show itself and the content therein.
2022-11-2448 min
pharmaphorum PodcastLive from Frontiers Health 2022 - the pharmaphorum podcastIn this special, live edition of the pharmaphorum podcast, recorded at the conclusion of Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock and pharmaphorum Web Editor Nicole Raleigh are joined by author, consultant, and podcast host Tony Estrella and Healthware Labs Managing Director Kristin Milburn to discuss their key takeaways from the show last week in Milan.
2022-10-2729 min
pharmaphorum PodcastUnderstanding the tumour micro-environment – the pharmaphorum podcastDr Marie-Louise Fjällskog, chief medical officer at Faron Pharmaceuticals, joins host Jonah Comstock for the pharmaphorum podcast this week to give us a primer on the tumour micro-environment, what it is, how we understand it, and what it means for the future of cancer care.
2022-10-0620 min
pharmaphorum PodcastInnovative solutions to the drug pricing crisis: the pharmaphorum podcastIn the newest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Dr Colin Banas, chief medical officer at DrFirst.
They discuss out of control drug pricing, especially in the United States, that has led to nonadherence and care rationing
2022-04-2923 min
pharmaphorum PodcastBig data and how it can change the game in pharma: the pharmaphorum podcastIn the latest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Miruna Sasu, chief strategy officer of COTA and long-time pharma vet - before joining COTA last year, she headed up J&J’s Clinical Trial Feasibility and Advanced Analytics Team and led the Digital Health and Innovation Team at Bristol Myers Squibb.
2022-03-2330 min
pharmaphorum PodcastThe year ahead in digital health and life sciences: the pharmaphorum podcastIn the latest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe).
Tune in to hear about the year ahead in digital health and life sciences, as well as the need for partnership and collaboration more broadly between the pharma and tech worlds. Goldsack reports on what she heard in the virtual events surrounding JP Morgan this year, and then puts some of those insights into context out of her own experience.
2022-02-1026 min
pharmaphorum PodcastThe evolution of clinical trials: the pharmaphorum podcastIn the latest episode of the pharmaphorum podcast, Dr Paul Tunnah speaks to head of Patient Engagement at Syneos Health, Marie Emms, and Elligo Health Research vice president, strategic partnerships, Keith Fern.
Together they discuss the changing nature of clinical trials how COVID-19 impacted the sector, and the role technology is playing in supporting trial enrolment and retention.
2022-01-1443 min
pharmaphorum PodcastPatient engagement processes: the pharmaphorum podcastThis episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led clinician, consultant and patient advocate, Mark Duman.
2021-12-1740 min
pharmaphorum PodcastMerck on trends in oncology: the pharmaphorum podcastEpisode 45 of the pharmaphorum podcast heard from Dr Stuart Hill, how he’s seen the oncology landscape change and which of those he sees holding the most potential to improve patient outcomes.
2021-11-1217 min
pharmaphorum PodcastPatient engagement strategies: the pharmaphorum podcastThis episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate.
2021-10-2934 min
pharmaphorum PodcastBMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcastEpisode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of pharma commercialisation and communications.
2021-10-1525 min
pharmaphorum PodcastNovartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcastEpisode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team mitigated disruption to Novartis’ own operations.
2021-10-0424 min
pharmaphorum PodcastPharmacy and clinical research: the pharmaphorum podcastIn the latest episode of the pharmaphorum podcast, pharmaphorum’s web editor Catherine Longworth speaks to Gerald Finken, the founder and CEO of RxE2.
The US-based company was founded in 2019 and is on a mission to bring the practice of pharmacy into clinical research.
2021-06-3035 min
pharmaphorum PodcastPharma’s post-COVID prospects: the pharmaphorum podcastIn this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season.
2021-05-2814 min
pharmaphorum PodcastGalapagos UK’s Michael Smyth on COVID and RNA-based tech: the pharmaphorum podcastEpisode 35 of the pharmaphorum podcast heard from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit.
2021-04-3017 min
pharmaphorum PodcastBig data and cell therapy development: the pharmaphorum podcastIn the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr. Darrin Disley, CEO of UK biotech Mogrify
2021-04-201h 01
pharmaphorum PodcastNew ways to treat COVID: the pharmaphorum podcastIn episode 31 of the pharmaphorum podcast, Deep Dive editor George Underwood speaks to RedHill biopharma’s chief business officer Guy Goldberg about the potential for new COVID-19 therapeutics to help fight the pandemic and treat patients in the years to come.
2021-03-1219 min
pharmaphorum PodcastRichard Francis discusses his new role as Purespring’s CEO: pharmaphorum podcastIn this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month.
Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma company’s executive committee.
2021-02-1214 min
pharmaphorum PodcastAstraZeneca’s Rebekah Martin on diversity and inclusion: the pharmaphorum podcastThe theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by AstraZeneca’s Rebekah Martin.
Serving as senior vice president of reward and inclusion at AstraZeneca, Rebekah discussed how the pharmaceutical industry approaches the promotion of diversity.
In an episode that was recorded in December 2020, she also talked about what inclusion and diversity mean to her company.
2021-01-2924 min
pharmaphorum PodcastJ&J and medical device innovation: the pharmaphorum podcastIn episode 27 of the pharmaphorum podcast I’m joined by Erin McEachren, who’s EU Regional Vice President at J&J Surgical Vision.
She talks about her priorities at J&J, having joined the company six months ago, the current state of the medical devices sector and some of the trends she’s keeping a close eye on.
2020-12-2116 min
pharmaphorum PodcastBiotech trends in COVID era: the pharmaphorum podcastIn episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical company Pharnext.
2020-11-3017 min
pharmaphorum PodcastAlnylam, gene-silencing and biotech in 2020: the pharmaphorum podcastAnlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic.
2020-08-2719 min
pharmaphorum PodcastNovartis, company culture and COVID-19: the pharmaphorum podcastNovartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face
2020-07-3000 minpharmaphorum PodcastNovartis, company culture and COVID-19: the pharmaphorum podcastNovartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face
2020-07-3020 min
pharmaphorum PodcastRoche, big data and patient outcomes: the pharmaphorum podcastIn the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data
2020-01-0800 minpharmaphorum PodcastRoche, big data and patient outcomes: the pharmaphorum podcastIn the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data
2020-01-0831 min
pharmaphorum PodcastPfizer and the UK cancer landscape: the pharmaphorum podcastPfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK
2019-12-1100 minpharmaphorum PodcastPfizer and the UK cancer landscape: the pharmaphorum podcastPfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK
2019-12-1128 min
pharmaphorum PodcastLife sciences leadership: the pharmaphorum podcastEpisode 15 of the pharmaphorum podcast marked a return visit for leading life sciences industry authority Professor Brian
2019-11-1400 minpharmaphorum PodcastLife sciences leadership: the pharmaphorum podcastEpisode 15 of the pharmaphorum podcast marked a return visit for leading life sciences industry authority Professor Brian
2019-11-1442 min
pharmaphorum PodcastAstraZeneca and lung cancer: the pharmaphorum podcastThis episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, Global Franchise Head, Tagrisso TDR
2019-08-0721 minpharmaphorum PodcastAstraZeneca and lung cancer: the pharmaphorum podcastThis episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, Global Franchise Head, Tagrisso TDR
2019-08-0700 min
pharmaphorum PodcastLung cancer’s patient information gap: the pharmaphorum podcastFor episode 13 of the pharmaphorum podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s
2019-08-0626 minpharmaphorum PodcastLung cancer’s patient information gap: the pharmaphorum podcastFor episode 13 of the pharmaphorum podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s
2019-08-0600 min
pharmaphorum PodcastThe state of UK drug discovery: the pharmaphorum podcastThe UK environment for drug discovery, the impact of artificial intelligence (AI) on medicines research and the role of complex cell models were all on the agenda for episode 12 of the pharmaphorum podcast.
On it I spoke with Chris Molloy, who’s CEO at the UK’s Medicines Discovery Catapult, about the Catapult’s State of the Discovery Nation publication, a joint report with the UK’s biotech trade body the BioIndustry Association.
2019-07-1932 min
pharmaphorum PodcastAddressing global health challenges: the pharmaphorum podcastFor episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to record a special roundtable episode in Philadelphia with the International AIDS Vaccine Initiative (IAVI).
2019-06-1959 min
pharmaphorum PodcastGene therapy and market access: the pharmaphorum podcastFor episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.
The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.
2019-05-3120 min
pharmaphorum PodcastAMR research and Matoke Pharma: the pharmaphorum podcastRe-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a crucial step on the UK biotech company’s plans to target antimicrobial resistance (AMR).
In episode 9 of the pharmaphorum podcast Alan Westwood explains the research behind Matoke’s SurgihoneyRO, an antimicrobial wound gel that has a CE mark in Europe, and how the company is taking that product’s reactive oxygen (RO) component to develop novel pharmaceutical antimicrobials.
2019-05-1324 min
pharmaphorum PodcastGSK and digital disruption: the pharmaphorum podcastDigital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which I visited GlaxoSmithKline at their Stockley Park base to speak with Kai Gait, a senior global digital strategy director at the company.
2019-04-0528 min
pharmaphorum PodcastIpsen on neurotoxin research: the pharmaphorum podcastFor episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.
2019-03-2811 min
pharmaphorum PodcastSuccessful medical marketing teams: the pharmaphorum podcastThe pharmaphorum podcast’s first episode of 2019 features Professor Brian D Smith on what makes a modern, and successful, medical marketing team.
2019-02-2225 minpharmaphorum PodcastBiotech strategy and nanomedicine: the pharmaphorum podcastFor episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Collection in London to talk about the UK biotech he co-founded, its strategy and bringing innovation to life through Blueberry’s nanomedicine approach.
2018-12-2120 minpharmaphorum PodcastCommercialising orphan drugs: the pharmaphorum podcastIn episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.
2018-11-2017 minpharmaphorum PodcastThe future biosimilar landscape: the pharmaphorum podcastFor episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the company’s UK specialty business Kavya Gopal.
2018-10-1641 minpharmaphorum PodcastNimble consumer healthcare innovation: the pharmaphorum podcastIn episode 2 of the podcast pharmaphorum talked to the CEO of Infirst Healthcare Manfred Scheske about how he’s seen the consumer health sector develop.
2018-09-1431 min